MX2018012545A - Reactivos para el tratamiento de distrofia muscular oculofaríngea (opmd) y su uso. - Google Patents
Reactivos para el tratamiento de distrofia muscular oculofaríngea (opmd) y su uso.Info
- Publication number
- MX2018012545A MX2018012545A MX2018012545A MX2018012545A MX2018012545A MX 2018012545 A MX2018012545 A MX 2018012545A MX 2018012545 A MX2018012545 A MX 2018012545A MX 2018012545 A MX2018012545 A MX 2018012545A MX 2018012545 A MX2018012545 A MX 2018012545A
- Authority
- MX
- Mexico
- Prior art keywords
- opmd
- treatment
- muscular dystrophy
- reagents
- oculopharyngeal muscular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
Abstract
La presente divulgación se refiere a reactivos de ARN de interferencia (ARNi) para el tratamiento de la distrofia muscular oculofaríngea (OPMD), a composiciones que comprenden los mismos y al uso de los mismos para tratar a individuos que padecen OPMD o que están predispuestos a la misma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662322745P | 2016-04-14 | 2016-04-14 | |
PCT/AU2017/050330 WO2017177277A1 (en) | 2016-04-14 | 2017-04-13 | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018012545A true MX2018012545A (es) | 2019-06-10 |
Family
ID=60041243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012545A MX2018012545A (es) | 2016-04-14 | 2017-04-13 | Reactivos para el tratamiento de distrofia muscular oculofaríngea (opmd) y su uso. |
Country Status (15)
Country | Link |
---|---|
US (1) | US11234994B2 (es) |
EP (1) | EP3443091A4 (es) |
JP (1) | JP7236195B2 (es) |
KR (1) | KR102353847B1 (es) |
CN (1) | CN109219659B (es) |
AU (1) | AU2017250017B2 (es) |
BR (1) | BR112018071186A8 (es) |
CA (1) | CA3020754C (es) |
IL (1) | IL262337B2 (es) |
MX (1) | MX2018012545A (es) |
NZ (1) | NZ747314A (es) |
RU (1) | RU2755544C2 (es) |
SG (1) | SG11201808981XA (es) |
WO (1) | WO2017177277A1 (es) |
ZA (1) | ZA201807589B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ747314A (en) | 2016-04-14 | 2022-07-29 | Benitec Ip Holdings Inc | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
BR112019012312A8 (pt) * | 2016-12-14 | 2023-02-28 | Benitec Biopharma Ltd | Reagentes para tratamento da distrofia muscular oculofaríngea (opmd) e uso dos mesmos |
EP3866859A4 (en) * | 2018-10-17 | 2023-08-09 | Benitec IP Holdings Inc. | METHODS OF TREATMENT FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
MY107332A (en) | 1990-08-03 | 1995-11-30 | Sterling Drug Inc | Compounds and methods for inhibiting gene expression. |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
JPH08508491A (ja) | 1993-03-31 | 1996-09-10 | スターリング ウインスロップ インコーポレイティド | ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
US6054576A (en) | 1997-10-02 | 2000-04-25 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA |
ATE443528T1 (de) | 1998-01-05 | 2009-10-15 | Univ Washington | Erhöhter transport unter benutzung membranzerstörender stoffe |
US7273933B1 (en) | 1998-02-26 | 2007-09-25 | Isis Pharmaceuticals, Inc. | Methods for synthesis of oligonucleotides |
US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
US6465628B1 (en) | 1999-02-04 | 2002-10-15 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
WO2001053307A1 (en) | 2000-01-21 | 2001-07-26 | Geron Corporation | 2'-arabino-fluorooligonucleotide n3'→p5'phosphoramidates: their synthesis and use |
EP1313752B1 (en) | 2000-09-01 | 2011-04-20 | Ribozyme Pharmaceuticals, Inc. | Methods for synthesizing nucleoside derivatives |
ES2728168T3 (es) | 2000-12-01 | 2019-10-22 | Max Planck Gesellschaft | Moléculas pequeñas de ARN que median en la interferencia de ARN |
US20020130430A1 (en) | 2000-12-29 | 2002-09-19 | Castor Trevor Percival | Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products |
US7514099B2 (en) | 2005-02-14 | 2009-04-07 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
CA2448120A1 (en) | 2001-05-24 | 2002-11-28 | Genzyme Corporation | Muscle-specific expression vectors |
US7060498B1 (en) | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
US20030215395A1 (en) | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US6989442B2 (en) | 2002-07-12 | 2006-01-24 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
US7897380B2 (en) | 2002-08-29 | 2011-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Circular nucleic acid vectors, and methods for making and using the same |
EP2213738B1 (en) * | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
US7358223B2 (en) | 2004-10-04 | 2008-04-15 | Nitto Denko Corporation | Biodegradable cationic polymers |
WO2006074166A2 (en) | 2005-01-06 | 2006-07-13 | Benitec, Inc. | Rnai agents for maintenance of stem cells |
US8110184B2 (en) * | 2005-09-30 | 2012-02-07 | University Of Kentucky Research Foundation | Ex vivo and in vivo methods and related compositions for generating hematopoietic stem cell populations |
EP2014281A1 (en) | 2007-06-19 | 2009-01-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. |
EP2326331A4 (en) | 2008-08-18 | 2013-05-15 | Merck Sharp & Dohme | NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION |
WO2010042877A1 (en) | 2008-10-09 | 2010-04-15 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
CN104922699B (zh) | 2009-03-12 | 2020-07-24 | 阿尔尼拉姆医药品有限公司 | 脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法 |
US9181295B2 (en) | 2009-08-20 | 2015-11-10 | Sirna Therapeutics, Inc. | Cationic lipids with various head groups for oligonucleotide delivery |
IN2012DN06588A (es) * | 2010-02-10 | 2015-10-23 | Novartis Ag | |
RU2639549C2 (ru) | 2010-12-30 | 2017-12-21 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Молекулы нуклеиновых кислот, которые придают устойчивость к насекомым-вредителям отряда жесткокрылых |
KR101454425B1 (ko) * | 2012-10-11 | 2014-11-03 | 포항공과대학교 산학협력단 | 미리세틴을 유효성분으로 포함하는 운동수행능력 증강용 조성물 |
WO2014077693A1 (en) | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
KR101683964B1 (ko) * | 2014-05-29 | 2016-12-09 | 연세대학교 산학협력단 | Daxx의 발현을 억제하는 핵산 분자, TRAIL 유전자 및 Bcl-xL 의 발현을 억제하는 핵산 분자를 포함하는 재조합 발현 벡터 |
NZ747314A (en) | 2016-04-14 | 2022-07-29 | Benitec Ip Holdings Inc | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
-
2017
- 2017-04-13 NZ NZ747314A patent/NZ747314A/en unknown
- 2017-04-13 JP JP2018554006A patent/JP7236195B2/ja active Active
- 2017-04-13 BR BR112018071186A patent/BR112018071186A8/pt active Search and Examination
- 2017-04-13 RU RU2018138271A patent/RU2755544C2/ru active
- 2017-04-13 EP EP17781644.4A patent/EP3443091A4/en active Pending
- 2017-04-13 WO PCT/AU2017/050330 patent/WO2017177277A1/en active Application Filing
- 2017-04-13 US US16/093,493 patent/US11234994B2/en active Active
- 2017-04-13 MX MX2018012545A patent/MX2018012545A/es unknown
- 2017-04-13 CN CN201780034592.0A patent/CN109219659B/zh active Active
- 2017-04-13 AU AU2017250017A patent/AU2017250017B2/en active Active
- 2017-04-13 CA CA3020754A patent/CA3020754C/en active Active
- 2017-04-13 SG SG11201808981XA patent/SG11201808981XA/en unknown
- 2017-04-13 KR KR1020187032992A patent/KR102353847B1/ko active IP Right Grant
-
2018
- 2018-10-14 IL IL262337A patent/IL262337B2/en unknown
- 2018-11-12 ZA ZA2018/07589A patent/ZA201807589B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL262337B2 (en) | 2023-06-01 |
SG11201808981XA (en) | 2018-11-29 |
BR112018071186A8 (pt) | 2023-03-28 |
CA3020754C (en) | 2023-07-25 |
KR20180133500A (ko) | 2018-12-14 |
US11234994B2 (en) | 2022-02-01 |
WO2017177277A1 (en) | 2017-10-19 |
EP3443091A4 (en) | 2019-11-27 |
KR102353847B1 (ko) | 2022-01-21 |
CA3020754A1 (en) | 2017-10-19 |
US20200138849A1 (en) | 2020-05-07 |
BR112018071186A2 (pt) | 2019-02-12 |
EP3443091A1 (en) | 2019-02-20 |
JP7236195B2 (ja) | 2023-03-09 |
RU2755544C2 (ru) | 2021-09-17 |
RU2018138271A (ru) | 2020-05-14 |
CN109219659A (zh) | 2019-01-15 |
RU2018138271A3 (es) | 2020-09-22 |
AU2017250017A1 (en) | 2018-11-08 |
AU2017250017B2 (en) | 2022-12-22 |
IL262337A (en) | 2018-11-29 |
CN109219659B (zh) | 2022-09-09 |
NZ747314A (en) | 2022-07-29 |
JP2019513395A (ja) | 2019-05-30 |
ZA201807589B (en) | 2023-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018014152A (es) | Composiciones y métodos para tratar la enfermedad de huntington. | |
MX2022004101A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
PH12018501268A1 (en) | Compounds useful as kinase inhibitors | |
WO2016106401A3 (en) | Rna agents for p21 gene modulation | |
MX2021006053A (es) | Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas. | |
EP3995581A3 (en) | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders | |
JO3558B1 (ar) | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) | |
PH12015501953A1 (en) | Substituted nucleotide analogs | |
MY192888A (en) | Dna alkylating agents | |
MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
PH12014501106B1 (en) | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases | |
PH12019500626A1 (en) | Aav treatment of huntington's disease | |
MX2018009750A (es) | Composiciones potenciadoras de vcn y métodos para su uso. | |
PH12019550076A1 (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
MX363846B (es) | Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos. | |
PH12020550195A1 (en) | Use of p38 inhibitors to reduce expression of dux4 | |
WO2019060432A3 (en) | Gapmers and methods of using the same for treatment of muscular dystrophy | |
MX2018012545A (es) | Reactivos para el tratamiento de distrofia muscular oculofaríngea (opmd) y su uso. | |
MX2019007110A (es) | Reactivos para el tratamiento de la distrofia muscular oculofaringea (opmd) y uso de estos. | |
WO2017059122A8 (en) | Methods of treating and preventing amyotrophic lateral sclerosis | |
EA201890884A1 (ru) | Способ и композиции для нежелательных и аномальных мышечных сокращений | |
WO2014153209A8 (en) | Antisense oligonucleotides for treatment of cancer stem cells | |
GB2507700A (en) | Compositions and methods for treatment of metastatic cancer | |
MX2021007271A (es) | Nuevas moleculas de acido nucleico conjugado y sus usos. | |
WO2015020993A3 (en) | RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA |